Investment Rating - The industry investment rating is maintained at "Overweight" [7] Core Insights - The report highlights the continuous upgrading of policies in the Heilongjiang biomanufacturing industry, focusing on innovative traditional Chinese medicine and innovative medical devices [4] - The report emphasizes the significant revisions to the Drug Administration Law, which provides institutional support for pharmaceutical innovation and high-quality development [4] - The report identifies three major transformations in China's innovative drug business development (BD) in 2026: technology output combined with product authorization, platform cooperation, and global parallel innovation [8] Summary by Sections Industry Performance - Over the past 12 months, the industry has shown a relative return of -7.06% compared to the CSI 300 index, with an absolute return of 11.53% [3] Investment Highlights - The report notes that BD transactions in the pharmaceutical sector are focused on unmet clinical needs, technological differentiation, and global value [6] - Key areas of focus include oncology therapies such as dual antibodies, ADCs, and TCE combinations, with significant financial agreements highlighted, such as a $650 million upfront payment for a PD-1/VEGF dual antibody [6] - The metabolic disease sector is centered on long-acting GLP-1 and small nucleic acid precision therapies, with notable collaborations resulting in substantial upfront payments and potential total amounts [6] Company-Specific Developments - Companies like Andover Pharmaceuticals and Frontier Biotech have secured significant collaborations with major pharmaceutical firms, indicating a trend towards platform-based cooperation and technology output [7] - Specific collaborations include a $1.05 billion deal for a CTLA-4 inhibitor and a $400 million agreement for small nucleic acid drugs, showcasing the growing interest in innovative therapies [7] - The report suggests monitoring companies such as Rebio Biotech and WuXi AppTec for their advancements in small nucleic acids and platform capabilities [8]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology sector [7] Core Views - The report highlights that the pharmaceutical index decreased by 2.40% during the week of November 3-7, underperforming both the CSI 300 index and the ChiNext index. It emphasizes that some companies in the innovative drug sector have entered the second phase of industry development [12][18] - The report suggests that the innovative drug sector is experiencing a temporary adjustment phase, driven more by trading impacts than fundamental factors. It anticipates a potential market shift that could lead to a new round of growth in the innovative drug sector over the next 5-10 years, with a focus on "disruption" rather than revaluation [13][14] Summary by Sections 1. Industry Performance Review - The pharmaceutical index's performance was characterized by a V-shaped recovery, with the innovative drug sector continuing to adjust while flu-related stocks performed well [2][12] - The report notes that the innovative drug sector is currently not the market's focus, leading to individual stock-driven performance [13] 2. Future Outlook - The report outlines a strategy to continue exploring innovative drugs in preparation for a potential rebound in Q4-Q1, focusing on overseas large pharmaceuticals and small to mid-cap technology revolutions [14] - It expresses optimism for the innovative drug sector leading into 2025, identifying key themes such as overseas large pharmaceuticals, small to mid-cap technology revolutions, and the revaluation of generic drugs [14] 3. Investment Strategy - The report provides a detailed investment strategy for innovative drugs, highlighting key companies such as Innovent Biologics, 3SBio, and others in various therapeutic areas including oncology and chronic diseases [15][16] - It also emphasizes the importance of new technologies like brain-computer interfaces and AI in pharmaceuticals, as well as the internationalization of medical devices [16] 4. Subsector Analysis - The report indicates that the innovative drug index decreased by 3.63% during the same week, underperforming the pharmaceutical index and the CSI 300 index [33] - It highlights the performance of the generic drug sector, which decreased by 4.56%, and notes the challenges faced by traditional Chinese medicine companies due to market pressures [39][48]